Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii

Article metrics

Abstract

Polymyxins, an old class of antibiotics, are currently used as the last resort for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii. However, recent pharmacokinetic and pharmacodynamic data indicate that monotherapy can lead to the development of resistance. Novel approaches are urgently needed to preserve and improve the efficacy of this last-line class of antibiotics. This study examined the antimicrobial activity of novel combination of polymyxin B with anthelmintic closantel against A. baumannii. Closantel monotherapy (16 mg l−1) was ineffective against most tested A. baumannii isolates. However, closantel at 4–16 mg l−1 with a clinically achievable concentration of polymyxin B (2 mg l−1) successfully inhibited the development of polymyxin resistance in polymyxin-susceptible isolates, and provided synergistic killing against polymyxin-resistant isolates (MIC 4 mg l−1). Our findings suggest that the combination of polymyxin B with closantel could be potentially useful for the treatment of MDR, including polymyxin-resistant, A. baumannii infections. The repositioning of non-antibiotic drugs to treat bacterial infections may significantly expedite discovery of new treatment options for bacterial ‘superbugs’.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2

References

  1. 1

    Boucher, H. W. et al. 10 x '20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56, 1685–1694 (2013).

  2. 2

    Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E. & Li, J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol. 8, 711–724 (2013).

  3. 3

    Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538–582 (2008).

  4. 4

    Dudhani, R. V., Turnidge, J. D., Nation, R. L. & Li, J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65, 1984–1990 (2010).

  5. 5

    Garonzik, S. M. et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55, 3284–3294 (2011).

  6. 6

    Poulikakos, P., Tansarli, G. S. & Falagas, M. E. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur. J. Clin. Microbiol. Infect. Dis. (2014).

  7. 7

    Cai, Y., Chai, D., Wang, R., Liang, B. & Bai, N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67, 1607–1615 (2012).

  8. 8

    Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348–350 (2011).

  9. 9

    Li, J. et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50, 2946–2950 (2006).

  10. 10

    Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54, 4971–4977 (2010).

  11. 11

    Pelletier, M. R. et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 57, 4831–4840 (2013).

  12. 12

    Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect 18, 268–281 (2012).

  13. 13

    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement (M100-S22). (2012).

  14. 14

    Bergen, P. J. et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob. Agents Chemother. 55, 5134–5142 (2011).

  15. 15

    Pillai, S. K., Moellering, R. C. & Eliopoulos, G. M in Antibiotics in Laboratory Medicine (ed. Victor Lorian) Ch. 9, (Lippincott Williams & Wilkins, 2005).

  16. 16

    Cheah, S. E., Li, J., Nation, R. L. & Bulitta, J. B. Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies. Antimicrob. Agents Chemother. 59, 381–388 (2015).

  17. 17

    Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12 (2009).

  18. 18

    Vincent, J. L. et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302, 2323–2329 (2009).

  19. 19

    Kunz, A. N. & Brook, I. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy 56, 492–500 (2010).

  20. 20

    Li, J. et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6, 589–601 (2006).

  21. 21

    Falagas, M. E. & Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333–1341 (2005).

  22. 22

    Ko, K. S. et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60, 1163–1167 (2007).

  23. 23

    Owen, R. J., Li, J., Nation, R. L. & Spelman, D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 59, 473–477 (2007).

  24. 24

    Tan, C. H., Li, J. & Nation, R. L. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 51, 3413–3415 (2007).

  25. 25

    Nation, R. L. et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect. Dis. 15, 225–234 (2015).

  26. 26

    Martin, R. J. Modes of action of anthelmintic drugs. Vet. J. 154, 11–34 (1997).

  27. 27

    Gloeckner, C. et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc. Natl. Acad. Sci. USA 107, 3424–3429 (2010).

  28. 28

    Williamson, R. L. & Metcalf, R. L. Salicylanilides: a new group of active uncouplers of oxidative phosphorylation. Science 158, 1694–1695 (1967).

  29. 29

    Omura, S Ivermectin: 25 years and still going strong. Int J. Antimicrob. Agents 31, 91–98 (2008).

  30. 30

    Michiels, M., Meuldermans, W. & Heykants, J. The metabolism and fate of closantel (Flukiver) in sheep and cattle. Drug Metab. Rev. 18, 235–251 (1987).

  31. 31

    Mohammed-Ali, N. A. & Bogan, J. A. The pharmacodynamics of the flukicidal salicylanilides, rafoxanide, closantel and oxyclosanide. J. Vet. Pharmacol. Ther. 10, 127–133 (1987).

  32. 32

    Sandri, A. M. et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J. Antimicrob. Chemother. 68, 674–677 (2013).

  33. 33

    Zavascki, A. P., Goldani, L. Z., Li, J. & Nation, R. L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60, 1206–1215 (2007).

  34. 34

    Lean, S. S. et al. Prevalence and genetic characterization of carbapenem- and polymyxin-resistant Acinetobacter baumannii isolated from a tertiary hospital in Terengganu, Malaysia. ISRN Microbiol. 2014, 953417 (2014).

  35. 35

    Freire, M. P. et al. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl. Infect. Dis. 16, 369–378 (2014).

  36. 36

    Velkov, T. et al. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun. 20, 350–363 (2014).

  37. 37

    Moskowitz, S. M. et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 56, 1019–1030 (2012).

  38. 38

    Urban, C., Tiruvury, H., Mariano, N., Colon-Urban, R. & Rahal, J. J. Polymyxin-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 55, 388–389 (2011).

  39. 39

    Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. (Tokyo) 66, 571–591 (2013).

  40. 40

    Schaberle, T. F. & Hack, I. M. Overcoming the current deadlock in antibiotic research. Trends Microbiol. 22, 165–167 (2014).

  41. 41

    Conly, J. & Johnston, B. Where are all the new antibiotics? The new antibiotic paradox. Can. J. Infect. Dis. Med. Microbiol. 16, 159–160 (2005).

  42. 42

    Poudyal, A. et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62, 1311–1318 (2008).

  43. 43

    Keepers, T. R., Gomez, M., Celeri, C., Nichols, W. W . & Krause, K. M Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58, 5297–5305 (2014).

  44. 44

    Robin, F. et al. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli. J. Antimicrob. Chemother. 66, 1052–1056 (2011).

  45. 45

    Hlasta, D. J. et al. Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. Bioorg Med. Chem. Lett. 8, 1923–1928 (1998).

  46. 46

    Macielag, M. J. et al. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J. Med. Chem. 41, 2939–2945 (1998).

  47. 47

    Rajamuthiah, R. et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS ONE 9, e89189 (2014).

  48. 48

    Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure—activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898–1916 (2010).

  49. 49

    Hancock, R. E. & Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 43, 1317–1323 (1999).

  50. 50

    Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol 3, 238–250 (2005).

  51. 51

    Pristovsek, P. & Kidric, J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study. J. Med. Chem. 42, 4604–4613 (1999).

  52. 52

    Hale, J. D. & Hancock, R. E. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 5, 951–959 (2007).

  53. 53

    Sampson, T. R. et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob. Agents Chemother. 56, 5642–5649 (2012).

Download references

Acknowledgements

This study is supported by a research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI111965) awarded to JL, TV, JNS, AF, AWP and DJC. YD is supported in part by R01AI104895. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. JL and AWP are Australian National Health and Medical Research Council (NHMRC) Senior Research Fellows. TV is an Australian NHMRC Industry Career Development Research Fellow and DJC is an Australian NHMRC Career Development Research Fellow.

Author information

Correspondence to Jian Li.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on The Journal of Antibiotics website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading